Rationale for Targeting Galectin-1 in Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Tumors of the head and neck are very hypoxic, Nambiar says, and Gal-1 is one of the hypoxia-responsive genes, meaning it gets induced during hypoxia.

Additonally, Nambiar says that T-cell responses in tumors are very much limited when they have higher levels of Gal-1.